Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL102293 | 1.00 | PARP1 (0.46) | PARP1USP2SMN1; SMN2HSD17B10CHRM2 | |
| SCHEMBL102292 | 1.00 | PARP1 (0.46) | PARP1USP2SMN1; SMN2HSD17B10CHRM2 | |
| Potassium SCHEMBL30616188 | 0.98 | PARP1 (0.45) | PARP1USP2SMN1; SMN2HSD17B10CHRM2 | |
| Methane SCHEMBL28975622 | 0.98 | PARP1 (0.45) | PARP1USP2SMN1; SMN2HSD17B10CHRM2 | |
| Hydrochloric Acid SCHEMBL377440 | 0.98 | PARP1 (0.45) | PARP1USP2SMN1; SMN2HSD17B10CHRM2 | |
| Urea SCHEMBL4458708 | 0.95 | PARP1 (0.43) | PARP1USP2SMN1; SMN2HSD17B10DPP4 | |
| SCHEMBL25212939 | 0.90 | PARP1 (0.41) | PARP1USP2SMN1; SMN2HSD17B10HPGD | |
| SCHEMBL25268281 | 0.90 | PARP1 (0.41) | PARP1USP2SMN1; SMN2HSD17B10HPGD | |
| SCHEMBL25416105 | 0.90 | PARP1 (0.41) | PARP1USP2SMN1; SMN2HSD17B10HPGD | |
| SCHEMBL22604987 | 0.88 | HPGD (0.41) | PARP1SMN1; SMN2HSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1218 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146042-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2026-05-28 | — | — | US | disclosed |
| EP-4747258-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | Tenvie Therapeutics, Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4747248-A1 | COMPOUNDS FOR USE IN A METHOD OF TARGETED PROTEIN DEGRADATION | Institute of Cancer Research: Royal Cancer Hospital (The) (GB) | 2026-05-27 | — | — | EP | disclosed |
| US-12637458-B2 | Imidazo[1,2-a]pyridine compounds and their use in therapy | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2026-05-26 | — | — | US | disclosed |
| WO-2026106929-A1 | DIHYDROQUINAZOLINES USEFUL AS CYTOMEGALOVIRUS ANTIVIRAL AGENTS | ASSEMBLY BIOSCIENCES, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| WO-2026107406-A1 | p53 HETEROBIFUNCTIONAL CONJUGATES AND USES THEREOF | Design Therapeutics, Inc. (US) | 2026-05-21 | — | — | WO | disclosed |
| WO-2026106389-A1 | NMT INHIBITOR AND USE THEREOF | 주식회사 이노보테라퓨틱스 | 2026-05-21 | — | — | WO | disclosed |
| EP-4029868-B1 | MCL-1 INHIBITORS | GILEAD SCIENCES INC (US) | 2026-05-20 | — | — | EP | disclosed |
| US-12630559-B2 | Spirocyclic-substituted 6,7-dihydro-pyrano[2,3- d]pyrimidine inhibitors of KRAS G12C mutant | MERCK SHARP & DOHME LLC (US) | 2026-05-19 | — | — | US | disclosed |
| US-20260132143-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2026-05-14 | — | — | US | disclosed |
| CN-1778800-A | Chiral piperazine substrated quinolone carboxylic acid derivative, and preparation and use thereof | SHANGHAI PHARMACEUTIC INST CHI (CN) | 2006-05-31 | — | — | CN | disclosed |
| US-20060040968-A1 | 2-(Amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. | 2006-02-23 | — | — | US | disclosed |
| EP-1499319-A4 | BICYCLO 4.4.0 ANTIVIRAL DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2006-02-08 | — | — | EP | disclosed |
| WO-2005066139-A2 | 2-(AMINO-SUBSTITUTED)-4-ARYL PYRAMIDINES AND RELATED COMPOUNDS USEFUL FOR TREATING INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-07-21 | — | — | WO | disclosed |
| CN-1629146-A | Process for synthesis of chiral 2-substituted piperazine and its derivatives | SHANGHAI INST MATERIA MEDICA (CN) | 2005-06-22 | — | — | CN | disclosed |
| EP-1381366-A4 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC AMIDOPIPERAZINE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2005-02-16 | — | — | EP | disclosed |
| EP-1499319-A1 | BICYCLO 4.4.0 ANTIVIRAL DERIVATIVES | Bristol-Myers Squibb Company (US) | 2005-01-26 | — | — | EP | disclosed |
| EP-1381366-A2 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC AMIDOPIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-01-21 | — | — | EP | disclosed |
| WO-2003092695-A1 | BICYCLO 4.4.0 ANTIVIRAL DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-11-13 | — | — | WO | disclosed |
| WO-2002085301-A2 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC AMIDOPIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260146042-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | CDK9, CDK6, CDK7 | PARP1 3042/4885USP2 3299/4885SMN1; SMN2 3529/4885 |
| US-20260132143-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | KRAS, NRAS, HRAS | PARP1 2339/4885USP2 1960/4885SMN1; SMN2 2043/4885 |
| US-20060040968-A1 | 2-(Amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases | PRKCZ, PRKCQ, PRKCE | PARP1 1880/4885USP2 3660/4885SMN1; SMN2 3964/4885 |
| US-12630559-B2 | Spirocyclic-substituted 6,7-dihydro-pyrano[2,3- d]pyrimidine inhibitors of KRAS G12C mutant | KRAS, NRAS, HRAS | PARP1 1009/4885USP2 1859/4885SMN1; SMN2 2361/4885 |
| US-12637458-B2 | Imidazo[1,2-a]pyridine compounds and their use in therapy | OGFR, CBR3, CBR1 | PARP1 2439/4885USP2 4064/4885SMN1; SMN2 2108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.